Holding(s) in Company

RNS Number : 1324W

Hikma Pharmaceuticals Plc

06 February 2017

 

Notification of major interests in shares

LONDON, 6 February 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

2	Reason for the notification
	An acquisition or disposal of voting rights	Yes
	An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached	No
	An event changing the breakdown of voting rights	No
	Other (please specify): Compliance with the Transparency Directive	No

3	Full name of the person subject to the notification obligation					The Capital Group Companies, Inc.
4	Full name of shareholders					Refer to section 9
5	Date of the Transaction (and date on which the threshold crossed is reached differently)					1 February 2017
6	Date on which the issuer notified					3 February 2017
7	Threshold that is crossed					10%
8	Notified details					See A, B & C below
A. Voting rights attached to shares
Class type of shares (if possible using the ISIN code)		Situation previous to the triggering transaction		Resulting situation after the triggering transaction
		Number of shares	Number of voting rights	Number of shares	Number of voting rights		% of voting rights
				Direct	Direct	Indirect	Direct	Indirect
Ordinary Shares (0.10 GBP) GB00B0LCW083		22,321,334	22,321,334			24,161,334		10.0691%

B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights that may be acquired if the instrument if exercised/converted	% of voting rights
-	-	-	-	-

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Exercise Price	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights instrument refers to	% of voting rights
					Nominal	Delta
-	-	-	-	-	-	-

Total A+B+C
Number of Voting rights	% of voting rights
24,161,334	10.0691%

9	Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable
	Number of Shares Percent of Outstanding The Capital Group Companies, Inc. ("CG") holdings 24,161,334 10.0691% Holdings by CG Management Companies and Funds: • Capital Research and Management Company 24,161,334 10.0691%

Proxy Voting
10	Name of the proxy holder	N/A
11	Number of voting rights proxy holder will cease to hold:
12	Date on which proxy holder will cease to hold voting rights:

13	Additional Information
14	Contact name:	Christopher Aquino
15	Contact telephone number:	+001 [phone]

- ENDS -

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million. 

 

END

 

 

HOLUNSURBSAURAR